Argenx SE

Argenx SE unveils 2025 full‑year results and Q4 update: see revenue trends, pipeline progress, and market positioning in its Feb. 26 webcast.

Argenx shares swing after FDA grants priority review for Vyvgart’s new myasthenia gravis indication, boosting outlook and revealing the company’s strategy to diversify beyond oncology.

Argenx’s VYVGART gains FDA priority‑review for seronegative generalized myasthenia gravis, offering early, evidence‑based hope for a rare, underserved patient group.

Argenx SE’s biotech stock climbs on a premium valuation driven by its antibody platform, breakthrough CD73 oncology trials, and strong autoimmune data—an attractive blend of scientific promise and market confidence for investors.

Argenx SE’s new CEO signals a bold shift toward next‑gen antibody therapies, backed by a “Buy” rating and a revised target price, driving investor confidence and global expansion plans.

Argenx SE’s split analyst ratings reflect its strong revenue base but rising R&D costs and regulatory hurdles, with pipeline prospects like TNB‑585 and BMS‑986192 driving debate.

Argenx’s antibody‑engineering expertise fuels a diversified pipeline—autoimmune and oncology—while AI‑driven design cuts lead‑generation time, positioning the Dutch biotech for 18% revenue growth.

Argenx stops its Phase‑3 efgartigimod trial for thyroid eye disease, yet remains a bullish investment with FDA‑approved therapies, robust pipeline, and steady analyst support.

Argenx’s phase‑III TED trial halt sparks a brief stock dip, yet investors stay bullish on its diversified pipeline, strong cash, and strategic partnerships, showing resilience amid challenges.

Argenx shares rise on strong oncology data and a diversified bispecific pipeline, highlighting AMG 557’s melanoma success and future regulatory prospects.